Nov 28, 2018
Prometic Provides Corporate Update
Nov 14, 2018
Prometic Reports Third Quarter 2018 Financial Results and Highlights
Nov 12, 2018
Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast
Aug 07, 2018
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
Apr 03, 2018
Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer
Mar 28, 2018
Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities
Jan 25, 2018
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
Dec 11, 2017
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
Nov 13, 2017
Prometic Reports 2017 Third Quarter Highlights and Financial Results
Nov 09, 2017
Prometic to Report its Third Quarter 2017 Financial Results and to Hold Conference Call / Webcast
Nov 02, 2017
For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !
Nov 01, 2017
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation
Oct 26, 2017
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer Phase 2 clinical trial
Oct 20, 2017
Prometic presents PBI-4050 and PBI-4547 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting
Aug 14, 2017
Prometic Reports 2017 Second Quarter Highlights and Financial Results